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Recent results show that a-tocopheryl succinate (a-TOS) is a proapoptotic agent with antineoplastic activity. As modifications of the
vitamin E (VE) molecule may affect its apoptogenic activity, we tested a number of newly synthesised VE analogues using malignant
cell lines. Analogues of a-TOS with lower number of methyl substitutions on the aromatic ring were less active than a-TOS.
Replacement of the succinyl group with a maleyl group greatly enhanced the activity, while it was lower for the glutaryl esters.
Methylation of the free succinyl carboxyl group on a-TOS and d-TOS completely prevented the apoptogenic activity of the parent
compounds. Both Trolox and its succinylated derivative were inactive. a-tocotrienol (a-T3 H) failed to induce apoptosis, while g-T3 H
was apoptogenic, and more so when succinylated. Shortening the aliphatic side chain of g-T3 by one isoprenyl unit increased its
activity. Neither phytyl nor oleyl succinate caused apoptosis. These findings show that modifications of different functional moieties of
the VE molecule can enhance apoptogenic activity. It is hoped that these observations will lead to the synthesis of analogues with
even higher apoptogenic and, consequently, antineoplastic efficacy.
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Current therapies for neoplastic disease, although often effective in
causing remission, frequently lead to deleterious and even life-
threatening side-effects. Therefore, there is great interest in
developing otherwise nontoxic but effective antineoplastic agents,
and inducers of apoptosis may fall into this category of agents
(Ferreira et al, 2002). In this regard, recent findings suggest that
certain analogues of vitamin E (VE), such as a-tocopheryl
succinate (a-TOS), may represent a new class of antineoplastic
agents with high selectivity for malignant cells and low toxicity.
a-Tocopheryl succinate causes apoptotic death of a variety of
neoplastic cell lines (Fariss et al, 1994; Qian et al, 1997; Neuzil et al,
1999; Yamamoto et al, 2000), whereas neither the redox-active
a-tocopherol (a-TOH) nor its uncharged ester, a-tocopheryl acetate
(a-TOA), is effective (Qian et al, 1997; Neuzil et al, 2001c).
Therefore, the proapoptotic activity appears to be a unique feature
of a-TOS, and this agent is also effective in vivo, inhibiting the
growth of colon (Weber et al, 2002) and melanoma cancers (Malafa
et al, 2001), promoting breast cancer dormancy (Malafa and
Neitzel, 2000), and suppressing metastasis (Barnett et al, 2002).
These intriguing observations have prompted us to investigate the
molecular properties responsible for this interesting and evidently
selective (Neuzil et al, 2001b) proapoptotic action of a-TOS.
The apparent selective toxicity of a-TOS towards malignant vs
normal cells (Neuzil et al, 2001b, c; Weber et al, 2002) may be
related to its negative charge at neutral pH, a notion supported by
findings that its apoptotic action is enhanced at acidic pH (Neuzil
et al, 2002b). The selective toxicity may thus arise from the fact
that pH of the interstitium of most tumours is 6.2–6.5, but in the
range of 7.0–7.4 for most normal tissues (Gerweck and Seetharam,
1996). Another possible mechanism by which VE analogues may
exert selectivity is because of higher esterase activity of normal
compared to malignant cells. Epithelial intestinal cells as well as
hepatocytes are known to hydrolyse agents like a-TOS, while
Jurkat T lymphoma cells are inefficient, whereby accumulating
high levels of the toxic agent (Weber et al, 2003). The importance
of the acidic environment is further supported by a recent
observation that chlorambucil, a weak acid, exerted more
profound antineoplastic effects when pH of the tumour inter-
stitium was lowered (by hyperglycaemia) in an animal model of
breast cancer (Kozin et al, 2001).
These findings suggest that modifications of individual func-
tional moieties of VE analogues might modulate proapoptotic
activity. We therefore synthesised novel analogues of VE differing
from a-TOS in the ester side group, in the number and positions of
methyl substitutions on the aromatic ring, and in the aliphatic side
chain. We show here that these modifications change the original
proapoptotic activity of a-TOS, either positively or negatively,
depending on the type of modifications and their combination.
MATERIALS AND METHODS
Chemicals
a-D-tocopherol (a-TOH; 1), g-D-tocopherol (g-TOH; 3), a-D-
tocopheryl acetate (a-TOA; 5), and a-D-tocopheryl succinate (a-
TOS; 6) were from Sigma (Castle Hill, NSW, Australia), a-trolox
Received 30 September 2002; revised 11 March 2003; accepted 18
March 2003
*Correspondence: Dr J Neuzil, School of Health Sciences, Griffith
University Gold Coast Campus, Southport, 9726 Queensland, Australia;
E-mail: j.neuzil@mailbox.gu.edu.au
British Journal of Cancer (2003) 88, 1948–1955
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s(a-TroH; 13) was from Aldrich (Diesenhofen, Germany). b-D-
tocopherol (b-TOH; 2), d-D-tocopherol (d-TOH; 4), a-tocotrienol
(a-T3H; 18) and g-tocotrienol (g-T3H; 19) were kindly donated by
Henkel Inc. (Stockholm, Sweden). Anhydrides of succinic acid, maleic
acid, 2-methylsuccinic acid, glutaric acid, 3-methyl-glutaric acid, 3,3-
dimethylglutaric acid, and 2,2-dimethylglutaric acid were purchased
from Aldrich. Geranylaceton was purchased from Fluka (Diesenho-
fen, Germany). Methylene chloride was distilled over calcium hydride,
under a nitrogen atmosphere. The diazomethane solution in
ether was generated from Diazald, using a distillation apparatus with
Clear-Seal glass joints (both items were purchased from Aldrich).
Synthesis
General remarks: Coupled HPLC-electrospray ionisation mass
spectrometry (ESI-MS) was performed in negative ionisation.
Trimethylsilylether was analysed by GC/MS with electrochemical
ionisation.
1H NMR and
13C NMR spectra were recorded at 300
and 75.47MHz, respectively, on Bruker AMX 300 with CDCl3 as
solvent and TMS as internal standard. The carbon
13C values for
the phytyl side chain of tocopherol derivatives (C10 to C130) are not
listed, since they are only slightly affected by modifications of the
chroman structure and are well established (Rosenau and Kosma,
2001).
General procedure for tocopheryl- and fatty alcohol carboxylate
synthesis: Appropriate tocopherols/tocotrienols (4mmol) or fatty
alcohols (4mmol) were dissolved in 15ml of dry pyridine, and
dicarboxylic acid anhydrides were added in a 50% molar excess.
The solution was purged with argon and refluxed for 6–12h
depending on the substrates. The reaction mixture was poured into
100ml of 1 M HCl and extracted three times with diethylether. The
combined organic extracts were washed three times with 1 M HCl
and dried with Na2SO4. After solvent evaporation, the crude
product was purified by flash chromatography (4:2 hexane:ethyl
acetate). The yields ranged between 30 and 75%.
General procedure for methyl ester formation of tocopheryl
carboxylates. The tocopheryl carboxylate (0.16mmol) and dichlor-
omethane (1ml) were added to a scratch-free 25ml Erlenmeyer
flask. An ice-cold solution of diazomethane in ether (0.7ml, 0.3 M)
was added drop-wise to the flask with stirring. Nitrogen gas
evolved for several minutes, and the solution maintained a yellow
colour. The progress of the reaction was monitored by thin layer
chromatography; it was generally complete within 5min. Upon
completion, a dilute solution of acetic acid in methanol was
added drop-wise, until the yellow colour disappeared and it
became colourless. The solvent was removed by rotary evapora-
tion, followed by placement under high vacuum (0.1Torr). This
reaction generally provides quantitative yields of the desired
methyl ester (pure by TLC). Flash column chromatography of the
product is optional. This can be performed in hexane/ethyl acetate
(10:1) to provide a sample for analytical characterisation.
RRR-a-tocopheryl maleate (a-TOM; 7). Brown semisolid;
1H
NMR (CDCl3) d 0.84 (d, 3 H), 0.86 (d, J¼6.6Hz, 6 H), 0.87 (d, 3
H), 1.25 (s, 3 H), 1.1–1.5 (m, 19 H), 1.5–1.6 (m, 2 H), 1.79 (m, 2
H), 1.98 (s, 3 H), 2.02 (s, 3 H), 2.10 (s, 3 H), 2.60 (t, J¼6.9Hz, 2 H),
7.14 (AB, J¼15.6Hz, 2 H);
13C NMR (CDCl3) d 11.8, 12.1, 13.0,
20.6, 24.4, 30.9, 75.2, 117.6, 123.3, 123.9, 126.4, 2 135.0, 140.0,
149.8, 2 169.2; ESI-MS (m/z): 527 (MH
þ).
RRR-a-tocopheryl 2-methylsuccinate (a-TO2MS; 8). Yellow semi-
solid;
1H NMR (CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86
(d, J¼6.6Hz, 6 H), 0.87 (d, J¼6.4Hz, 3 H), 1.23 (s, 3 H), 1.1–
1.5 (m, 19 H), 1.46 (d, J¼7.2Hz, 3 H), 1.5–1.6 (m, 2 H), 1.77 (m, 2
H), 1.96 (s, 3 H), 2.00 (s, 3 H), 2.08 (s, 3 H), 2.60 (t, J¼6.9Hz, 2 H),
2.6–2.8 (m, 1 H), 2.9–3.1 (m, 2 H);
13C NMR (CDCl3) d 11.8, 12.0,
12.9, 17.0, 20.6, 24.4, 31.1, 35.6, 37.0, 75.0, 117.3, 123.2, 124.9, 126.5,
140.4, 149.4, 173.6, 177.7; ESI-MS (m/z): 543 (MH
þ).
RRR-a-tocopheryl glutarate (a-TOG; 9). Yellow semisolid;
1H
NMR (CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86 (d, J¼6.6Hz, 6 H),
0.87 (d, J¼6.4Hz, 3 H), 1.23 (s, 3 H), 1.1–1.5 (m, 19 H), 1.5–1.6
(m, 2 H), 1.7–1.9 (m, 2 H), 1.96 (s, 3 H), 2.00 (s, 3 H), 2.09 (s, 3 H),
2.1–2.2 (m, 2 H), 2.54 (t, J¼7.2Hz, 2 H), 2.57 (t, J¼5.1Hz, 2 H),
2.70 (t, J¼7.5Hz, 2 H);
13C NMR (CDCl3) d 11.8, 12.1, 13.0, 20.2,
20.6, 24.4, 31.1, 32.9, 33.0, 75.2, 117.4, 122.9, 125.1, 126.6, 140.4,
149.4, 171.4; ESI-MS (m/z): 543 (MH
þ).
RRR-a-tocopheryl 3-methylglutarate (a-TO3MG; 10). Yellow
semisolid; 1H NMR (CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86 (d,
J¼6.6Hz, 6 H), 0.87 (d, J¼6.4Hz, 3 H), 1.23 (s, 3 H), 1.1–1.5 (m,
20 H), 1.17 (d, J¼6.0Hz, 3 H), 1.5–1.6 (m, 2 H), 1.7–1.9 (m, 2 H),
1.97 (s, 3 H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.4 (m, 2 H), 2.58 (t,
J¼7.2Hz, 2 H), 2.7 (m, 2 H);
13C NMR (CDCl3) d 11.8, 12.2, 13.0,
19.9, 20.6, 24.4, 27.1, 31.1, 40.2, 40.4, 75.0, 117.4, 123.0, 124.7, 126.6,
140.5, 149.4, 170.8, 178.0; ESI-MS (m/z): 557 (MH
þ).
RRR-a-tocopheryl 3,3-dimethylglutarate (a-TO33DMG; 11) Yel-
low semisolid;
1H NMR (CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86 (d,
J¼6.6Hz, 6 H), 0.87 (d, J¼6.4Hz, 3 H), 1.23 (s, 3 H), 1.1–1.5 (m,
19 H), 1.25 (s, 6 H), 1.5–1.6 (m, 2 H), 1.7–1.9 (m, 2 H), 1.97 (s, 3
H), 2.01 (s, 3 H), 2.08 (s, 3 H), 2.58 (m, 2 H), 2.62 (s, 2 H), 2.79 (s, 2
H);
13C NMR (CDCl3) d 11.8, 12.3, 13.1, 20.6, 24.4, 28.0, 31.1,
2 32.4, 43.9, 44.5, 75.0, 117.3, 123.0, 124.9, 126.7, 140.5, 149.4,
170.8, 177.2; ESI-MS (m/z): 571 (MH
þ).
RRR-a-tocopheryl 2,2-dimethylglutarate (a-TO22DMG; 12) Yel-
low semisolid;
1H NMR (CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86 (d,
J¼6.6Hz, 6 H), 0.87 (d, J¼6.4Hz, 3 H), 1.23 (s, 3 H), 1.1–1.5 (m,
19 H), 1.30 (s, 6 H), 1.5–1.6 (m, 2 H), 1.7–1.9 (m, 2 H), 1.96 (s, 3
H), 2.00 (s, 3 H), 2.08 (s, 3 H), 2.1 (m, 2 H), 2.58 (t, J¼6.6Hz, 2 H),
2.65 (m, 2 H);
13C NMR (CDCl3) d 11.8, 12.1, 13.0, 20.6, 24.4, 24.8,
24.9, 30.0, 31.1, 35.0, 41.6, 75.0, 117.4, 123.0, 124.9, 126.6, 140.4,
149.4, 171.9, 183.1; ESI-MS (m/z): 571 (MH
þ).
Trolox succinate (TroS; 14) Brown solid;
1H NMR (CDCl3) d 1.64
(s, 3 H), 1.91 (s, 3 H), 2.00 (s, 3 H), 2.15 (s, 3 H), 2.4 (m, 2 H), 2.6
(m, 2 H), 2.76–3.1 (m, 4 H);
13C NMR (CDCl3), d 11.3, 12.0, 12.9,
20.5, 25.1, 28.7, 28.9, 31.1, 76.2, 117.2, 123.1, 124.2, 125.4, 140.8,
145.1, 170.3, 172.6, 174.8; ESI-MS (m/z): 349 (MH
þ).
RRR-d-tocopheryl succinate (d-TOS; 17) Yellow semisolid;
1H
NMR (CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86 (d, J¼6.6Hz, 6 H),
0.87 (d, J¼6.4Hz, 3 H), 1.23 (s, 3 H), 1.1–1.5 (m, 19 H), 1.5–1.6
(m, 2 H), 1.77 (m, 2 H), 2.14 (s, 3 H), 2.60 (t, J¼6.9Hz, 2 H), 2.80–
2.84 (m, 4 H), 6.6–6.7 (m, 2 H);
13C NMR (CDCl3) d 16.1, 19.6, 19.7,
30.0, 22.4, 22.6, 22.7, 24.4, 24.8, 28.0, 28.9, 28.9, 31.0, 32.7, 32.8,
37.2, 37.4, 40.2, 75.0, 118.9, 2 121, 127.3, 142.3, 149.8, 171.3, 177.8;
ESI-MS (m/z): 501 (MH
þ).
R-g-tocotrienyl succinate (g-T3S; 20) Yellow semisolid;
1H NMR
(CDCl3) d 1.26 (s, 3 H), 1.60 (s, 9 H), 1.68 (s, 3 H), 1.5–1.9 (m, 2 H),
1.95–2.2 (m, 12 H), 2.01 (s, 3 H), 2.10 (s, 3 H), 2.71 (m, 2 H), 2.75–
2.95 (m, 4 H), 5.11 (m, 3 H), 6.57 (s, 1 H);
13C NMR (CDCl3) d 11.9,
12.6, 15.9, 16.0, 17.6, 22.2, 2 24.1, 25.7, 26.6, 26.8, 28.9, 28.9, 31.0,
2 39.7, 40.0, 75.0, 113.3, 118.4, 118.8, 124.2, 124.4, 125.9, 127.1,
131.2, 135.0, 135.2, 141.5, 149.46, 170.5, 171.2; ESI-MS (m/z): 509
(MH
þ).
Phytyl succinate (PYS; 22) Colourless semisolid;
1H NMR
(CDCl3) d 0.84 (d, J¼6.6Hz, 3 H), 0.86 (d, J¼6.6Hz, 6 H), 0.87
(d, J¼6.4Hz, 3 H), 1.1–1.5 (m, 19 H), 1.70 (s, 3 H), 1.95–2.15 (m,
2 H), 2.6 (m, 4 H), 4.62 (t, J¼6.9Hz, 2 H), 5.34 (m, 1 H);
13C NMR
(CDCl3) d 16.3, 2 19.7, 2 22.7, 24.5, 24.8, 28.0, 28.9, 29.0, 32.6,
32.7, 32.7, 32.8, 36.6, 36.8, 37.3, 37.4, 39.3, 61.8, 117.8, 143.1, 172.3,
178.1; ESI-MS (m/z): 395 (MH
þ).
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sOleyl succinate (OS; 23). Colourless semisolid;
1H NMR (CDCl3) d
0.88 (t, 3 H), 1.2–1.4 (m, 22 H), 1.62 (m, 2 H), 2.01 (m, 4 H), 2.66
(m, 4 H), 4.09 (t, J¼6.6Hz, 2 H), 5.35 (m, 2 H);
13C NMR (CDCl3) d
14.1, 22.7, 25.8, 2 27.2, 28.5,2 28.9, 2 29.2, 2 29.3, 29.4, 29.5,
29.7, 29.8, 31.9, 65.0, 129.8, 130.0, 172.2, 178.1; ESI-MS (m/z): 367
(MH
þ).
RRR-a-tocopheryl succinyl methyl ester (a-TOSM; 24). Clear
colourless oil; 1H NMR (CDCl3) d 0.85 (d, J¼6.6Hz, 3 H), 0.86
(d, J¼6.3Hz, 3 H), 0.87 (d, J¼6.6Hz, 6 H), 1.24 (s, 3 H), 1.02–
1.44, (m, 19 H), 1.46–1.60 (m, 2 H) , 1.74–1.82 (m, 2 H), 1.98 (s, 3
H), 2.02 (s, 3 H), 2.09 (s, 3 H), 2.59 (t, J¼6.7Hz, 2 H), 2.77 (m, 2
H), 2.94 (m, 2 H), 3.72 (s, 3 H);
13C NMR (CDCl3) 11.8, 12.0, 12.9,
19.6, 19.7, 20.6, 21.0, 22.6, 22.7, 24.4, 24.8, 28.0, 28.8, 28.9, 31.1,
32.7, 32.8, 37.3, 37.4, 39.3, 51.9, 75.0, 77.2, 117.3, 123.0, 124.9, 126.6,
140.4, 149.4, 170.9, 172.6.
RRR-d-tocopheryl succinyl methyl ester (d-TOSM; 25). Clear
colourless oil; 1H NMR (CDCl3) d 0.77 (d, J¼7.1Hz, 3 H), 0.78
(d, J¼6.6Hz, 3 H), 0.80 (d, J¼6.6Hz, 6 H), 1.18 (s, 3 H), 0.94–
1.39, (m, 19 H), 1.41 1.51 (m, 2 H), 1.62–1.75 (m, 2 H), 2.06 (s, 3
H), 2.63–2.68 (m, 4 H), 2.75-2.80 (m, 2 H), 3.65 (s, 3 H), 6.55 (d,
J¼2.5Hz, 1 H), 6.60 (d, J¼2.5Hz, 1 H);
13C NMR (CDCl3) d 16.1,
19.6, 19.7, 21.0, 22.4, 22.6, 22.7, 24.2, 24.4, 24.8, 28.0, 29.0, 29.3,
30.9, 32.7, 32.8, 37.3 37.41, 37.43, 39.4, 40.1, 51.9, 76.1, 77.2, 118.9,
120.9, 121.0, 127.3, 142.3, 149.8, 171.6, 172.6.
Synthesis of a-2-geranylchromanol. 2, 6, 10-trimethyl-10-hydroxy-2,
6, 11-dodecatriene Vinyl magnesium bromide (1 M in tetrahy-
drofuran, 6.4ml, 6.4mmol) was added with vigorous stirring under
argon at 0–51C to a solution of geranylaceton (1.2g, 6.2mmol) in
diethylether (100ml) over 60min. The reaction mixture was stirred
for additional 30min and acidified with 1 M HCl to pH 2, and
diluted with water to dissolve precipitated salts. This solution was
extracted with ether (3 100ml), and the combined ether extracts
washed with brine (3 50ml) and dried over Na2SO4. Ether was
removed on a rotavapor to yield yellow oil that was used without
further purification.
a-2-geranylchromanol (a-T2H; 21) Vinyl alcohol (0.96g, 4mmol)
in dioxane (2ml) was added over 1.5h at 1101C to a stirred
solution of 2,3,5-trimethylhydroquinone (0.42g, 2.8mmol) and
boron trifluoride etherate (0.7ml, 5.5mmol) in dioxane (15ml)
under argon. The reaction mixture was extracted with ethyl acetate
(3 100ml). The combined organic layers were washed with water,
dried over Na2SO4, concentrated under vacuum and applied to a
silica gel chromatography (hexane:ethyl acetate, 5:1) to yield
orange oil (285mg, 30%).
1H NMR (CDCl3) d 1.16 (s, 3 H), 1.60 (s,
6 H), 2.34 (s, 3 H), 1.95–2.2 (m, 6 H), 1.98 (s, 3 H), 2.01 (s, 3 H),
2.10 (s, 3 H), 2.69 (m, 2 H), 5.05 (m, 3 H);
13C-NMR (CDCl3) d 11.8,
11.9, 12.0, 17.8, 22.2, 2 24.1, 24.2, 25.7, 26.8, 31.0, 39.6, 40.3, 75.1,
118.4, 118.8, 124.4, 124.9, 125.9, 126.9, 131.0, 135.1, 145.2, 149.5; MS
(EI) m/z of trimethylsilylether: 428 (M
þ).
Cell culture and treatment
The human T lymphoma cell line Jurkat, neuroblastoma cell line
HTB11, and the breast carcinoma cell line MCF7 and its caspase-3-
expressing variant (Mathiasen et al, 1999) were used in the study.
Jurkat cells were maintained in the RPMI-1640 medium supple-
mented with 10% foetal calf serum (FCS) and antibiotics, while the
other lines were cultured in DMEM with 10% FCS and antibiotics.
Suspension cells (0.5 10
6 ml
 1) and adherent cells (50–70%
confluency) were exposed to individual agents at their concentra-
tion of up to 50mM for varying periods of time and assessed for
apoptosis as detailed below.
Apoptosis evaluation
Apoptosis was routinely assessed by the annexin V-binding
method, which is based on affinity of annexin V to phosphati-
dylserine externalised to the outer leaflet of the plasma membrane
early in the course of apoptosis (Neuzil et al, 2001a). In brief,
suspension cells were harvested by spinning down, while adherent
cells were detached by treatment with 2mM EDTA in PBS and
combined with the cells detached during treatment. The cells were
then washed with PBS, spun down, resuspended in the binding
buffer (10mM Hepes/NaOH, 140mM NaCl and 25mM CaCl2,p H7 . 4 ) ,
incubated with 2ml of annexin V–FITC (PharMingen, San Diego,
CA, USA), and analysed by flow cytometry (Becton Dickinson,
Rutherford, NJ, USA). In some cases, activation of caspase-3 was
assessed as follows. Treated cells were washed, permeabilised with
0.02% saponin in PBS, and incubated with an antibody raised
against activated caspase-3 (PharMingen) at room temperature for
60min. The cells were then washed and incubated with secondary
IgG conjugated to FITC at room temperature for additional 60min,
washed, and scored for FITC binding in a flow cytometer. The
percentage of apoptotic cells or cells with activated caspase-3 was
estimated by gating on the population with high fluorescence.
Unless specified otherwise, the data shown are mean values
7s.d. (n¼3). The asterisk at individual values indicates
statistically significant difference from the control with Po0.05,
as determined by the Student’s t-test.
RESULTS AND DISCUSSION
The molecule of VE can be divided into three functionally distinct
domains (Figure 1) (Neuzil et al, 2002a). Domain I (the functional
domain) is essential for the redox activity of VE analogues, which
involves the hydroxyl group in position C6 of the chromanol ring
structure. Interestingly, a-TOH does not induce apoptosis (Qian
et al, 1997; Neuzil et al, 2001c), nor does it when acetylated at C6
(a-TOA) (Neuzil et al, 2001a). However, succinylation in this
position makes a-TOH a strong apoptogen (Neuzil et al, 2001c).
Conversion of a-TOH into a charged species may thus play a role
O
O
Domains in VE analogues
HO
-TOH
-TOS
−OCOCH2CH2COO
Functional domain (I)
(responsible for
redox/apoptotic
activity)
(affects
PP2A/PKC
pathway)
Signalling
domain (II)
Hydrophobic domain (III)
(mediates docking
in membranes
and lipoproteins)
Figure 1 Functional domains in the molecule of VE. Vitamin E analogues
(represented here by a-TOH and a-TOS) comprise three distinct domains,
each responsible for a separate ‘function’ of the agent. Domain I, the
functional domain, decides whether the compound is redox-active or
redox-inactive. Domains II, the signalling domain, is responsible for effects of
the analogues such as deregulation of the protein kinase C/protein
phosphatase 2A pathway. Domain III, the hydrophobic domain, is
responsible for docking of VE analogues in biological membranes and
lipoproteins.
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sin apoptosis induction (Neuzil et al, 2002b). We therefore
investigated the effects of substituting a-TOS with other dicar-
boxylic acids in this position. Of these analogues, a-TOM was more
apoptogenic compared to a-TOS, whereas the other esters tested
were less effective than a-TOS in the order a-TO2MS 4a-TOG
4a-TO3MG 4a-TO33DMG¼a-TO22DMG (Figures 2 and 3).
Naturally occurring derivatives of a-TOH differ in the number
and position of methyl substitutions on the aromatic ring, that is
domain II (signalling domain). These include b-, g- and d-TOH. All
of these agents were largely nonapoptogenic (Neuzil et al, 2002a)
(Figure 4). Succinylation made them proapoptotic, although the
activity of b-, g- and d-TOS was lower than that of a-TOS, with
d-TOS being least apoptogenic (Figure 4). Their efficacy in
inhibiting protein kinase C also differs, and is not dependent on
their antioxidant capacity (Ricciarelli et al, 2001). In addition, the
substitution pattern is responsible for the rate of side chain
O
HO
CH3COO
−OOCCH2CH2COO
−OOCCH2CH(CH3)COO
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C OO−
HO
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O
−OOCCH2CH2COO
−OOCCH2CH2COO
−OOCCH2CH2COO
−OOCCH2CH2COO
−OOCCH2CH2COO
−OOCCH2CH2COO
−OOCCH2CH2COO
H3COOCCH2CH2COO
H3COOCCH2CH2COO
COO−
HO
HO
HO
14
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16
17
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19
20
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25
No. Acronym Name of analogue  No. Acronym  Name of analogue 
1   -TOH  -Tocopherol 
-Tocopherol 
-Tocopherol 
-Tocopherol 
14 -TroS -Trolox succinate 
2   15 -TOS -Tocopheryl succinate
3 16 -TOS -Tocopheryl succinate
4         17 -TOS -Tocopheryl succinate
5   -TOA   -Tocopheryl acetate  18 -T3H  -Tocotrienol
6   -TOS  -Tocopheryl succinate 19 -T3H  -Tocotrienol
7   -TOM  -Tocopheryl maleate  20 -T3S  -Tocotrienyl succinate
8   -TO2MS  -Tocopheryl 2-methylsuccinate 21 -T2H  -2-Geranylchromanol
9   -TOG   -Tocopheryl glutarate 22 PYS Phytyl succinate 
10   -TO3MG  -Tocopheryl 3-methylglutarate  23 OS Oleyl succinate
11   -TO33DMG   -Tocopheryl 3,3 dimethylglutarate 24 -TOSM  -Tocopheryl succinyl
methyl ester
12   -TO22DMG    25 -Tocopheryl succinyl
methyl ester
13   -TroH
-TOH 
-TOH 
-TOH 
 -Trolox 
-Tocopheryl 2,2-dimethylglutarate -TOSM 
Figure 2 Analogues of VE used in this study. The items shown in bold indicate newly synthesised compounds.
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sdegradation, as g- and d-TOH are degraded much faster than a-o r
b-TOH in cell culture (Birringer et al, 2001).
To address the importance of the free carboxylic group for
apoptogenic activity of VE dicarboxylic acid esters with saturated
isoprenyl side chains, we esterified a-TOS and d-TOS on the
succinyl moiety. The resulting methyl esters were completely
inactive as inducers of apoptosis in all cell lines tested (Figure 5).
Several modifications of the aliphatic side chain (domain III, the
hydrophobic domain) are possible. Its desaturation, in the case of
a-TOH, gives the naturally occurring a-T3H, which is nonapopto-
tic (Yu et al, 1999). g-T3H, however, has a strong apoptogenic
activity (Yu et al, 1999), which is further enhanced by its
conversion to g-T3S (Figure 6). Interestingly, a derivative of
g-T3H with the aliphatic side chain shorter by one isoprenyl unit,
a-T2H, exerted higher proapoptotic activity than did g-T3H itself
(Figure 6). Analogues of VE lacking the aliphatic side chain, that is,
a-TroH and a-TroS did not induce apoptosis, regardless of the
succinylation status (Figure 6).
Finally, we synthesised succinyl esters of long-chain fatty acids,
that is, PYS and OS. Neither of them caused any signs of apoptosis
at up to 100mM and at times of up to 48h (Figure 7). These results
indicate that presence of an aliphatic group at one end and a
chargeable moiety at the other end is not sufficient for apoptosis
induction and that presence of the chromanol structure may be
essential.
Toxicity of a-TOS towards cancer cells is known to be governed
by apoptotic signalling. To find out whether this form of cell death
is also involved in killing by the newly synthesised VE analogues,
we exposed Jurkat cells to the agents for increasing time, and
analysed the cells for caspase-3 activation, a hallmark of apoptotic
signalling. As demonstrated in Figure 8, all new VE analogues,
which were shown above to cause annexin V binding in several
cancer cell lines, caused time-dependent activation of caspase-3.
Assessment of annexin V binding was carried out on adherent and
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Figure 3 Effect of modifications in domain I of the VE molecule on their
apoptogenic activity. Jurkat (A), HBT11 (B), MCF7 (C), and MCF7-C3 cells
(D) were exposed for 24h to a-TOH, a-TOA, a-TOM, a-TOS, a-TO2MS,
a-TOG, a-TO3MG, a-TO33DMG, or a-TO22DMG (11), and assessed for
apoptosis using the annexin V–FITC method.
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Figure 4 Effect of modifications in domain II of the VE molecule on their
apoptogenic activity. Jurkat (A), HBT11 (B), MCF7 (C) and MCF7-C3 cells
(D) were exposed for 24h to a-TOH, b-TOH, g-TOH, d-TOH, a-TOS, b-
TOS, g-TOS, or d-TOS, and assessed for apoptosis using the annexin V–
FITC method.
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Figure 5 Effect of methylation of the succinyl moiety of VE succinyl
analogues on their apoptogenic activity. Jurkat (A), HBT11 (B), MCF7 (C)
and MCF7-C3 cells (D) were exposed for 24h to a-TOS, d-TOS, a-TOSM
or d-TOSM, and assessed for apoptosis using the annexin V–FITC method.
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sdetached cells pooled together (see Materials and Methods
section). It cannot be excluded that some of the cells died by
anoikis. However, similar effects wre observed with suspension,
Jurkat cells. This strongly suggests that apoptotic cell death is the
major mechanism by which these novel agents kill cancer cells.
The data presented herein suggest the following conclusions: (i)
Forms of VE with saturated aliphatic chains need to be esterified
with a dicarboxylic acid to exert apoptogenic activity. (ii) The
extent of proapoptotic effect is greatly dependent on the un-
saturation and length of the ester group substituent. Thus, the C6
maleyl-substituted analogue showed the highest activity, which
was virtually nondetectable in case of the 2,2-dimethyl- and 3,3-
dimethylglutaryl substituents. This may suggest that the appar-
ently less water-soluble agents are less bioavailable for the
malignant cells tested. Moreover, a-TOM may have higher in vivo
effectiveness as it is B10–20-fold more efficient in vitro than the
relatively well-studied a-TOS. The latter agent exerts antitumour
effects against experimental colon cancer at the pharmacologically
relevant blood levels of B40–50mM (Weber et al, 2002). We would
thus expect a-TOM to be equipotent with a-TOS in vivo at its
plasma levels of B5mM, that is, similar to those of circulating VE.
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Figure 6 Effect of modifications in domain III of the VE molecule on their
apoptogenic activity. Jurkat (A), HBT11 (B), MCF7 (C) and MCF7-C3 cells
(D) were exposed for 24h to a-TOH, a-TOS, a-T3H, g-T3H, g-T3S, a-
T2H, a-TroH, or a-TroS, and assessed for apoptosis using the annexin V–
FITC method.
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Figure 7 Proapoptotic activity of other structural analogues of VE. Jurkat
(A), HBT11 (B), MCF7 (C), and MCF7-C3 cells (D) were exposed for
24h to a-TOS, and for 22 or 48h to a-TOH, PYS, or OS, and assessed for
apoptosis using the annexin V–FITC method.
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Figure 8 Vitamin E analogues induce apoptosis and activate caspase-3.
Jurkat cells were exposed for the time shown to 50mM each of a-TOS, a-
TOM, a-TO2MS, a-TOG, a-TO3MG, g-T3H, g-T3S, or g-T2H, and
assessed for apoptosis extent (A) and caspase-3 activation using the
antibody specific for activated caspase-3 and a secondary, FITC-conjugated
antibody (B). The inset in (B) shows a typical histogram of flow cytometric
evaluation of control cell and cells treated with 50mM a-TOS for 12h.
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s(iii) Finally, and perhaps most importantly, the apoptogenic
activity of a-TOS and related derivatives does require a chargeable
substituent in position C6. This conclusion is supported by the fact
that a-TOS and a-TOA, while taken up at comparable rates
(Cheeseman et al, 1998), show a completely different apoptogenic
potential (cf Figure 3), and, in particular, by the finding that
esterification of the free carboxyl group on the succinyl moiety
completely obliterates apoptogenic activity of the parent com-
pounds (cf Figure 5).
One possible mechanism underlying the proapoptotic effects of
a-TOS and similar compounds may involve membrane destabilisa-
tion. a-Tocopheryl succinate has an aliphatic side chain, which
docks it in the lipid phase (Pussinen et al, 2000), and a hydrophilic
head group. In support of this notion, we observed detergent-like
effects of a-TOS using isolated erythrocytes or lysosomes (Neuzil
et al, 2002b). This suggested that many molecules with an aliphatic
chain on one end and a hydrophilic group on the other end could
induce apoptosis. To test this, we synthesised succinylated long-
chain aliphatic acids, that is, PYS and OS. However, these
compounds were nontoxic to all cell lines tested even following
prolonged exposure (cf Figure 7). Thus, it appears that the
apoptosis-inducing activity may require the presence of the
(bulky) chromanol structure, and this may still act through
promoting the destabilisation of phospholipid membranes. This
idea appears consistent with the finding that b-, g- and, especially,
d-TOS showed lower apoptogenic activity compared to that of
a-TOS, where all available positions on the aromatic ring are
substituted with methyl groups, although the protein kinase C
inhibitory activity of the a-tocopheryl-containing analogues also
contributes to the superior proapoptotic activity of a-TOS within
this group of agents (Neuzil et al, 2001c).
For VE analogues with saturated aliphatic side chains, the
presence of a chargeable ester group, such as succinyl or maleyl,
appears essential for apoptosis induction. However, polyunsatu-
rated forms of VE may exert proapoptotic activity even with the
redox-active hydroxyl group present. This is the case of g-T3H,
which, unlike a-T3H, causes apoptosis in a variety of malignant
cells (Yu et al, 1999; this report). An even stronger proapoptotic
effect was observed for g-T2H, a homologue of g-T3H with the
phenyl chain shorter by one isoprenyl unit. The mechanism
underlying apoptosis induction by g-T3H has not been studied, but
appears to differ from that involved in the action of a-TOS. One
possibility is that g-T3H acts via inhibition of prenylation
(Theriault et al, 2002). Indeed, other compounds, which block
prenylation, have been shown to be strong apoptogens (Miquel
et al, 1998; Rioja et al, 2000). It is tempting to hypothesise that
compounds like g-T3H or g-T2H may prevent carcinogenesis by
suppressing prenylation of crucial oncogenes, such as Ras (Adjei
2001), in which case these agents would have prophylactic effects.
One important difference between compounds like a-TOS and
g-T3H is that while a-TOS is largely selective for malignant cells
(Neuzil et al, 2001b, c; Weber et al, 2002), g-T3H is highly toxic
towards normal cells, such as primary fibroblasts or cardiomyo-
cytes (JN, unpublished). However, succinylation of g-T3H renders
the agent even more apoptogenic, and it will be interesting to
determine whether such modification makes the agent selective for
malignant cells, as might be expected in analogy to a-TOS. If so,
this would suggest that the addition of a chargeable ester group on
the aromatic ring may be a way of conferring selectivity to these
compounds. It is plausible that cultured cancer cells, because of
their very high metabolic activity, form a pH gradient across the
plasma membrane, promoting higher level of a-TOS uptake
in vitro. These notions are compatible with the concept that
inducers of apoptosis, which are weak acids, may be selectively
taken up by malignant cells due to the acidic interstitium of the
tumour (Gerweck and Seetharam, 1996; Kozin et al, 2001).
Overall, our findings indicate that modifications in all three
functional domains of VE analogues (cf Figure 1) modulate the
proapoptotic efficacy of the agents. Before testing the novel
compounds in vivo, we need to obtain information about their
stability. By analogy to previous results with a-tocopheryl
succinate (Weber et al, 2002), we expect gradual hydrolysis of
the esters primarily by hepatic esterases. Our recent data for a-TOS
suggest that, depending on the dosing regimen, the anticancer
form of the drug is retained in the circulation long enough to
suppress tumour growth. In any case, data presented in this
communication further strengthen the idea that this class of
compounds may hold substantial promise for the eventual
development of selective and nontoxic antineoplastic drugs, and
corresponding experiments are underway.
ACKNOWLEDGEMENTS
We thank Drs UT Brunk and JW Eaton for critical reading of the
manuscript. The assistance of C Birringer is highly appreciated.
We are indebted to W Engst (German Institute of Human
Nutrition, Potsdam-Rehbru ¨cke, Germany) for expert help with
LC-MS analysis. JN was partially supported by the University of
Linko ¨ping Grant 83081030 and a grant from the Dust Diseases
Board of Australia. JHE was supported by a Summer Research
Fellowship provided by Pfizer Inc.
REFERENCES
Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy.
J Natl Cancer Inst 93: 1062–1074
Barnett K, Fokum F, Malafa M (2002) Vitamin E succinate inhibits colon
cancer liver metastases. J Surg Res 106: 292–298
Birringer M, Drogan D, Brigelius-Flohe ´ R (2001) Tocopherols are
metabolized in HepG2 cells by side chain o-oxidation and consecutive
b-oxidation. Free Radic Biol Med 31: 226–232
Borel P, Pasquier B, Armand M, Tyssandier V, Grolier P, Alexandre-
Gouabau MC, Andre M, Senft M, Peyrot J, Jaussan V, Lairon D, Azais-
Braesco V (2001) Processing of vitamin A and E in the human
gastrointestinal tract. Am J Physiol 280: G95–G103
Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L, Burton G (1998)
Biokinetics of human RRR-a-tocopherol: the free phenol, acetate ester,
and succinate ester forms of vitamin E. Free Radic Biol Med 19: 591–598
Fariss MW, Fortuna MB, Everett K, Smith JD, Trent DF, Djuric Z (1994)
The selective antiproliferative effects of a-tocopheryl hemisuccinate and
cholesteryl hemisuccinate on murine leukemia cells result from the
action of the intact compounds. Cancer Res 54: 3346–3351
Fariss MW, Nicholls-Grzemski FA, Tirmenstein MA, Zhang JG (2001)
Enhanced antioxidant and cytoprotective abilities of vitamin E succinate
is associated with a rapid uptake advantage in rat hepatocytes and
mitochondria. Free Radic Biol Med 31: 530–541
Ferreira CG, Epping M, Kruyt FA, Giaccone G (2002) Apoptosis: target of
cancer therapy. Clin Cancer Res 8: 2024–2034
Gerweck LE, Seetharam K (1996) Cellular pH gradient in tumor versus
normal tissue: potential exploitation for the treatment of cancer. Cancer
Res 56: 1194–1198
Kogure K, Hama S, Manabe S, Tokumura A, Fukuzawa K (2002)
High cytotoxicity of a-tocopheryl hemisuccinate to cancer cells
is due to failure of their antioxidant defense systems. Cancer Lett 186:
151–156
Kozin SV, Shkarin P, Gerweck LE (2001) The cell transmembrane pH
gradient enhances cytotoxicity of specific weak acid chemotherapeutics.
Cancer Res 61: 4740–4743
Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M (2001) Vitamin E
inhibits melanoma growth in mice. Surgery 131: 85–91
VE analogues as inducers of apoptosis
M Birringer et al
1954
British Journal of Cancer (2003) 88(12), 1948–1955 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sMalafa MP, Neitzel LT (2000) Vitamin E succinate promotes breast cancer
tumor dormancy. J Surg Res 93: 163–170
Mathiasen IS, Lademann U, Ja ¨a ¨ttela ¨ M (1999) Apoptosis induced
by vitamin D compounds in breast cancer cells is inhibited by
Bcl-2 but does not involve known caspases or p53. Cancer Res 59:
4848–4856
Miquel K, Pradines A, Terce F, Selmi S, Favre G (1998) Competitive
inhibition of choline phosphotransferase by geranylgeraniol and farnesol
inhibits phosphatidylocholine synthesis and induces apoptosis in human
lung adenocarcinoma A549 cells. J Biol Chem 273: 26179–26186
Neuzil J, Ka ˚gedal K, Andera L, Weber C, Brunk UT (2002a) Vitamin E
analogs as a new class of multiple action agents: anti-neoplastic and anti-
atherogenic activity. Apoptosis 7: 177–185
Neuzil J, Schro ¨der A, von Hundelshausen P, Zernecke A, Weber T, Gellert
N, Weber C (2001a) Inhibition of inflammatory endothelial responses by
a pathway involving caspase activation and p65 cleavage. Biochemistry
40: 4686–4692
Neuzil J, Svensson I, Weber T, Weber C, Brunk UT (1999) a Tocopheryl
succinate-induced apoptosis in Jurkat T cells involves caspase-3
activation, and both lysosomal and mitochondrial destabilisation. FEBS
Lett 445: 295–300
Neuzil J, Weber T, Gellert N, Weber C (2001b) Selective cancer cell killing
by a-tocopheryl succinate. Br J Cancer 84: 87–89
Neuzil J, Weber T, Schro ¨der A, Lu M, Ostermann G, Gellert N, Mayne GC,
Olejnicka B, Ne `gre-Salvayre A, Sticha M, Coffey RJ, Weber C (2001c)
Induction of apoptosis in cancer cells by a-tocopheryl succinate:
molecular pathways and structural requirements. FASEB J 15: 403–415
Neuzil J, Zhao M, Ostermann G, Sticha M, Gellert N, Weber C, Eaton JW,
Brunk UT (2002b) a-Tocopheryl succinate, an agent with in vivo anti-
tumour activity, induces apoptosis by causing lysosomal instability.
Biochem J 362: 709–715
Pussinen PJ, Lindner H, Glatter O, Reicher H, Kostner GM, Wintersperger
A, Malle E, Sattler W (2000) Lipoprotein-associated a-tocopheryl-
succinate inhibits cell growth and induces apoptosis in human MCF-7
and HBL-100 breast cancer cells. Biochim Biophys Acta 1485: 129–144
Qian M, Kralova J, Yu W, Bose HR, Dvorak M, Sanders BG, Kline K (1997)
c-Jun involvement in vitamin E succinate induced apoptosis of
reticuloendotheliosis virus-transformed avian lymphoid cells. Oncogene
15: 223–230
Ricciarelli R, Zingg JM, Azzi A (2001) Vitamin E: protective role of a Janus
molecule. FASEB J 15: 2314–2325
Rioja A, Pizzey AR, Marson CM, Thomas NSB (2000) Preferential induction
of apoptosis of leukaemic cells by farnesol. FEBS Lett 467: 291–295
Rosenau T, Kosma P (2001) The ‘tocopherol-acetaminophen reaction’–a
new [1,4]-rearrangement discovered in vitamin E chemistry. Eur J Org
Chem 947–955
Theriault A, Chao JT, Gapor A (2002) Tocotrienol is the most effective
vitamin E for reducing endothelial expression of adhesion molecules and
adhesion to monocytes. Atherosclerosis 160: 21–30
Weber T, Dalen H, Andera L, Ne `gre-Salvayre A, Auge ´ N, Sticha M, Loret A,
Terman A, Witting PK, Higuchi M, Plasilova M, Zivny J, Gellert N, Weber
C, Neuzil J (2003) Mitochondria play a central role in apoptosis induced by
a-tocopheryl succinate, an agent with anticancer activity. Comparison with
receptor-mediated proapoptotic signaling. Biochemistry 42: 4277–4291
Weber T, Lu M, Andera L, Lahm H, Gellert N, Fariss MW, Korinek V,
Sattler W, Ucker DS, Terman A, Schro ¨der A, Erl W, Brunk UT, Coffey RJ,
Weber C, Neuzil J (2002) Vitamin E succinate is a potent novel anti-
neoplastic agent with high tumor selectivity and cooperativity with
tumor necrosis factor-related apoptosis-inducing ligand in vivo. Clin
Cancer Res 8: 863–869
Yamamoto S, Tamai H, Ishisaka R, Kanno T, Arita K, Kobuchi H, Utsumi K
(2000) Mechanism of a-tocopheryl succinate-induced apoptosis of
promyelocytic leukemia cells. Free Radic Res 33: 407–418
Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K (1999)
Induction of apoptosis in human breast cancer cells by tocopherols and
tocotrienols. Nutr Cancer 33: 26–32
VE analogues as inducers of apoptosis
M Birringer et al
1955
British Journal of Cancer (2003) 88(12), 1948–1955 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s